Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PULSE BIOSCIENCES, INC.PLSE · Entity 1151 | Director · Chief Technology Officer | March 23, 2026 | April 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PULSE BIOSCIENCES, INC.
Report date March 23, 2026 · Filed April 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2029-03-23 | Direct | 100,000 |
Reported balance
After 2026-03-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-23 · Grant · Acquired 100,000 · Balance 100,000 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's common stock. F2: The RSUs will fully vest on March 23, 2029, the three-year anniversary of the grant, subject to the Reporting Person's continued service through to that date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's common stock.
F2: The RSUs will fully vest on March 23, 2029, the three-year anniversary of the grant, subject to the Reporting Person's continued service through to that date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 23, 2026 Filed Apr 3, 2026 21:27 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantRestricted Stock Units · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-011291 · rdgdoc.xml · derivative · entry 1 UECKER DARRIN · CIK 0001276311 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-03-23 F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_date: The RSUs will fully vest on March 23, 2029, the three-year anniversary of the grant, subject to the Reporting Person's continued service through to that date. F2 · derivative.expiration_date: The RSUs will fully vest on March 23, 2029, the three-year anniversary of the grant, subject to the Reporting Person's continued service through to that date. Read SEC document |
| September 17, 2025 Filed Sep 19, 2025 00:44 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001437749-25-029432 · rdgdoc.xml · derivative · entry 10 UECKER DARRIN · CIK 0001276311 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2025-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Incentive stock options granted in connection with Reporting Person's hire became fully vested upon the four year anniversary of his Start Date, September 8, 2019, pursuant to the terms of his Employment Agreement dated September 8, 2015. Read SEC document |
| September 17, 2025 Filed Sep 19, 2025 00:44 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 61,534 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001437749-25-029432 · rdgdoc.xml · derivative · entry 9 UECKER DARRIN · CIK 0001276311 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 61,534 shares Expires 2025-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Options granted in connection with Reporting Person's hire became fully vested upon the four year anniversary of his Start Date, September 8, 2019, pursuant to the terms of his Employment Agreement dated September 8, 2015. Read SEC document |
| September 17, 2025 Filed Sep 19, 2025 00:44 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001437749-25-029432 · rdgdoc.xml · derivative · entry 8 UECKER DARRIN · CIK 0001276311 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,534 Underlying: Common Stock · 20,000 shares Expires 2025-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2025. F4 · derivative.exercise_date: Options granted in connection with Reporting Person's hire became fully vested upon the four year anniversary of his Start Date, September 8, 2019, pursuant to the terms of his Employment Agreement dated September 8, 2015. Read SEC document |
| September 17, 2025 Filed Sep 19, 2025 00:44 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 100,000 | $4.00 | $400,000.00 |
DisclosureSEC source: 0001437749-25-029432 · rdgdoc.xml · nonDerivative · entry 6 UECKER DARRIN · CIK 0001276311 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 284,406 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2025 Filed Sep 19, 2025 00:44 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 61,534 | $4.00 | $246,136.00 |
DisclosureSEC source: 0001437749-25-029432 · rdgdoc.xml · nonDerivative · entry 5 UECKER DARRIN · CIK 0001276311 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 184,406 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2025 Filed Sep 19, 2025 00:44 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | SaleCommon Stock | 20,000 | $16.21 | $324,200.00 |
DisclosureSEC source: 0001437749-25-029432 · rdgdoc.xml · nonDerivative · entry 4 UECKER DARRIN · CIK 0001276311 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,872 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2025. F3 · price: The price in column 4 is the weighted average price per share sold. The price per share actually received by the Reporting Person ranged from $16.00 to $16.44 per share. Read SEC document |
| September 17, 2025 Filed Sep 19, 2025 00:44 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 20,000 | $4.00 | $80,000.00 |
DisclosureSEC source: 0001437749-25-029432 · rdgdoc.xml · nonDerivative · entry 3 UECKER DARRIN · CIK 0001276311 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2025. Read SEC document |
| September 16, 2025 Filed Sep 19, 2025 00:44 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001437749-25-029432 · rdgdoc.xml · derivative · entry 7 UECKER DARRIN · CIK 0001276311 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,534 Underlying: Common Stock · 25,000 shares Expires 2025-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2025. F4 · derivative.exercise_date: Options granted in connection with Reporting Person's hire became fully vested upon the four year anniversary of his Start Date, September 8, 2019, pursuant to the terms of his Employment Agreement dated September 8, 2015. Read SEC document |
| September 16, 2025 Filed Sep 19, 2025 00:44 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | SaleCommon Stock | 25,000 | $16.28 | $407,000.00 |
DisclosureSEC source: 0001437749-25-029432 · rdgdoc.xml · nonDerivative · entry 2 UECKER DARRIN · CIK 0001276311 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,872 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2025. F2 · price: The price in column 4 is the weighted average price per share sold. The price per share actually received by the Reporting Person ranged from $15.49 to $16.78 per share. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes upon request by the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 16, 2025 Filed Sep 19, 2025 00:44 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 25,000 | $4.00 | $100,000.00 |
DisclosureSEC source: 0001437749-25-029432 · rdgdoc.xml · nonDerivative · entry 1 UECKER DARRIN · CIK 0001276311 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 147,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2025. Read SEC document |
| September 15, 2025 Filed Sep 16, 2025 01:09 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001437749-25-029104 · rdgdoc.xml · derivative · entry 9 UECKER DARRIN · CIK 0001276311 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,534 Underlying: Common Stock · 25,000 shares Expires 2025-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2025. F5 · derivative.exercise_date: Options granted in connection with Reporting Person's hire became fully vested upon the four year anniversary of his Start Date, September 8, 2019, pursuant to the terms of his Employment Agreement dated September 8, 2015. Read SEC document |
| September 15, 2025 Filed Sep 16, 2025 01:09 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | SaleCommon Stock | 25,000 | $15.77 | $394,250.00 |
DisclosureSEC source: 0001437749-25-029104 · rdgdoc.xml · nonDerivative · entry 6 UECKER DARRIN · CIK 0001276311 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,872 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2025. F4 · price: The price in column 4 is the weighted average price per share sold. The price per share actually received by the Reporting Person ranged from $15.18 to $17.20 per share. Read SEC document |
| September 15, 2025 Filed Sep 16, 2025 01:09 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 25,000 | $4.00 | $100,000.00 |
DisclosureSEC source: 0001437749-25-029104 · rdgdoc.xml · nonDerivative · entry 5 UECKER DARRIN · CIK 0001276311 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 147,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2025. Read SEC document |
| September 12, 2025 Filed Sep 16, 2025 01:09 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001437749-25-029104 · rdgdoc.xml · derivative · entry 8 UECKER DARRIN · CIK 0001276311 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,534 Underlying: Common Stock · 25,000 shares Expires 2025-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2025. F5 · derivative.exercise_date: Options granted in connection with Reporting Person's hire became fully vested upon the four year anniversary of his Start Date, September 8, 2019, pursuant to the terms of his Employment Agreement dated September 8, 2015. Read SEC document |
| September 12, 2025 Filed Sep 16, 2025 01:09 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | SaleCommon Stock | 25,000 | $14.32 | $358,000.00 |
DisclosureSEC source: 0001437749-25-029104 · rdgdoc.xml · nonDerivative · entry 4 UECKER DARRIN · CIK 0001276311 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,872 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2025. F3 · price: The price in column 4 is the weighted average price per share sold. The price per share actually received by the Reporting Person ranged from $13.80 to $14.76 per share. Read SEC document |
| September 12, 2025 Filed Sep 16, 2025 01:09 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 25,000 | $4.00 | $100,000.00 |
DisclosureSEC source: 0001437749-25-029104 · rdgdoc.xml · nonDerivative · entry 3 UECKER DARRIN · CIK 0001276311 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 147,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2025. Read SEC document |
| September 11, 2025 Filed Sep 16, 2025 01:09 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001437749-25-029104 · rdgdoc.xml · derivative · entry 7 UECKER DARRIN · CIK 0001276311 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,534 Underlying: Common Stock · 25,000 shares Expires 2025-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2025. F5 · derivative.exercise_date: Options granted in connection with Reporting Person's hire became fully vested upon the four year anniversary of his Start Date, September 8, 2019, pursuant to the terms of his Employment Agreement dated September 8, 2015. Read SEC document |
| September 11, 2025 Filed Sep 16, 2025 01:09 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | SaleCommon Stock | 25,000 | $14.78 | $369,500.00 |
DisclosureSEC source: 0001437749-25-029104 · rdgdoc.xml · nonDerivative · entry 2 UECKER DARRIN · CIK 0001276311 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,872 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2025. F2 · price: The price in column 4 is the weighted average price per share sold. The price per share actually received by the Reporting Person ranged from $14.41 to $15.14 per share. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes upon request by the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 11, 2025 Filed Sep 16, 2025 01:09 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 25,000 | $4.00 | $100,000.00 |
DisclosureSEC source: 0001437749-25-029104 · rdgdoc.xml · nonDerivative · entry 1 UECKER DARRIN · CIK 0001276311 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 147,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2025. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 00:23 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | SaleCommon Stock | 15,000 | $15.98 | $239,700.00 |
DisclosureSEC source: 0001437749-25-020563 · rdgdoc.xml · nonDerivative · entry 2 UECKER DARRIN · CIK 0001276311 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,872 F2 · price: The price in column 4 is the weighted average price per share sold. The price per share actually received by the Reporting Person ranged from $15.90 to $16.04 per share. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes upon request by the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 12, 2025 Filed Jun 17, 2025 00:23 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | SaleCommon Stock | 15,000 | $16.40 | $246,000.00 |
DisclosureSEC source: 0001437749-25-020563 · rdgdoc.xml · nonDerivative · entry 1 UECKER DARRIN · CIK 0001276311 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,872 F1 · price: The price in column 4 is the weighted average price per share sold. The price per share actually received by the Reporting Person ranged from $16.32 to $16.57 per share. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes upon request by the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 21:36 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 330,000 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001437749-23-030248 · rdgdoc.xml · derivative · entry 1 UECKER DARRIN · CIK 0001276311 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 330,000 Underlying: Common Stock · 330,000 shares Expires 2033-11-01 F1 · derivative.exercise_date: 100% vesting upon the earlier of (i) the six (6) year anniversary of the grant date, and (ii) the 1-year anniversary of a Company change of control. Read SEC document |
| July 12, 2023 Filed Jul 15, 2023 00:27 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 200,000 | Not disclosed Strike: $7.08 | Not disclosed |
DisclosureSEC source: 0001437749-23-019991 · rdgdoc.xml · derivative · entry 1 UECKER DARRIN · CIK 0001276311 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-07-12 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on July 12, 2023 under the Issuer's 2017 Equity Incentive Plan. The shares subject to the option are subject to two tranches of performance-based vesting criteria tied to Issuer's market capitalization, with no vesting until the Issuer's market capitalization exceeds $4 billion, in both cases, subject to the Reporting Person's continued service through each vesting milestone. Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 21:25 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherWarrant (right to buy) · Derivative | 7,365 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0001437749-23-017295 · rdgdoc.xml · derivative · entry 2 UECKER DARRIN · CIK 0001276311 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,365 shares Expires 2027-06-09 Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 21:25 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 7,365 | $2.05 | $15,098.25 |
DisclosureSEC source: 0001437749-23-017295 · rdgdoc.xml · nonDerivative · entry 1 UECKER DARRIN · CIK 0001276311 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 877,636 Read SEC document |
| June 12, 2023 Filed Jul 7, 2023 00:36 UTC Amendment | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherWarrant (right to buy) · Derivative | 7,365 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0001437749-23-019539 · rdgdoc.xml · derivative · entry 2 UECKER DARRIN · CIK 0001276311 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,365 shares Expires 2027-06-09 Read SEC document |
| June 12, 2023 Filed Jul 7, 2023 00:36 UTC Amendment | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 7,365 | $2.05 | $15,098.25 |
DisclosureSEC source: 0001437749-23-019539 · rdgdoc.xml · nonDerivative · entry 1 UECKER DARRIN · CIK 0001276311 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,941 F1 · balance_after: The number of shares beneficially owned, as reported on the Form 4 filed on June 13, 2023, erroneously included options held by the Reporting Person. Read SEC document |
| April 29, 2023 Filed May 3, 2023 01:45 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 500,000 | Not disclosed Strike: $6.44 | Not disclosed |
DisclosureSEC source: 0001437749-23-012179 · rdgdoc.xml · derivative · entry 1 UECKER DARRIN · CIK 0001276311 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2033-04-29 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on April 29, 2023 under the Issuer's 2017 Equity Incentive Plan. The shares subject to the option are subject to four tranches of performance-based vesting criteria tied to Issuer's market capitalization, with no vesting until the Issuer's market capitalization exceeds $1 billion, in all cases, subject to the Reporting Person's continued service through each vesting milestone. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 22:57 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseWarrant (right to buy) · Derivative | 7,365 | Not disclosed Strike: $2.05 | Not disclosed |
DisclosureSEC source: 0001387131-22-006921 · uecker-form4_060922.xml · derivative · entry 2 UECKER DARRIN · CIK 0001276311 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,365 Underlying: Common Stock · 7,365 shares Expires 2027-06-09 F2 · derivative.exercise_price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $2.05 per unit, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $2.05. F1 · kind: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and the Prospectus Supplement and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F1 · price: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and the Prospectus Supplement and certain Current Reports on Form 8-K filed by the Issuer with the SEC. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 22:57 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 7,365 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001387131-22-006921 · uecker-form4_060922.xml · nonDerivative · entry 1 UECKER DARRIN · CIK 0001276311 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,376 F1 · kind: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and the Prospectus Supplement and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F2 · price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $2.05 per unit, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $2.05. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 22:15 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 54,750 | $0.00 Strike: $24.03 | $0.00 |
DisclosureSEC source: 0001209191-21-022926 · doc4.xml · derivative · entry 2 UECKER DARRIN · CIK 0001276311 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,750 Underlying: Common Stock · 54,750 shares Expires 2031-03-22 F2 · derivative.exercise_date: The shares subject to the option will vest in equal annual installments over the following four years on the anniversary of March 1, 2021, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| February 23, 2021 Filed Mar 24, 2021 22:15 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 37,500 | $0.00 Strike: $10.66 | $0.00 |
DisclosureSEC source: 0001209191-21-022926 · doc4.xml · derivative · entry 1 UECKER DARRIN · CIK 0001276311 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2030-05-18 F1 · shares: Represents the acquisition of vested options upon the determination of the Compensation Committee of the Board of Directors of the Issuer that certain performance conditions were met in 2020 with respect to performance-based stock options granted to the Reporting Person on May 18, 2020. F1 · derivative.exercise_date: Represents the acquisition of vested options upon the determination of the Compensation Committee of the Board of Directors of the Issuer that certain performance conditions were met in 2020 with respect to performance-based stock options granted to the Reporting Person on May 18, 2020. Read SEC document |
| January 25, 2021 Filed Jan 26, 2021 21:12 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherWarrant (right to buy) · Derivative | 1,284 | $0.00 Strike: $7.01 | $0.00 |
DisclosureSEC source: 0001209191-21-005359 · doc4.xml · derivative · entry 2 UECKER DARRIN · CIK 0001276311 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,284 shares Expires 2025-06-15 Read SEC document |
| January 25, 2021 Filed Jan 26, 2021 21:12 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 1,284 | $7.01 | $9,000.84 |
DisclosureSEC source: 0001209191-21-005359 · doc4.xml · nonDerivative · entry 1 UECKER DARRIN · CIK 0001276311 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,893 Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:07 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseWarrant (right to buy) · Derivative | 1,284 | Not disclosed Strike: $7.01 | Not disclosed |
DisclosureSEC source: 0001209191-20-037230 · doc4.xml · derivative · entry 2 UECKER DARRIN · CIK 0001276311 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,284 Underlying: Common Stock · 1,284 shares Expires 2025-06-15 F1 · kind: The Reporting Person acquired the shares and warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering, as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F1 · price: The Reporting Person acquired the shares and warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering, as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:07 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 8,563 | $7.01 | $60,026.63 |
DisclosureSEC source: 0001209191-20-037230 · doc4.xml · nonDerivative · entry 1 UECKER DARRIN · CIK 0001276311 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,609 F1 · kind: The Reporting Person acquired the shares and warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering, as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. Read SEC document |
| June 03, 2019 Filed Jun 6, 2019 01:31 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Tax withholdingCommon Stock | 36,321 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-034965 · doc4.xml · nonDerivative · entry 1 UECKER DARRIN · CIK 0001276311 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,046 F1 · shares: The shares reflected on this Form 4 represent shares surrendered exclusively for the payment of tax obligations as set forth in Mr. Uecker's June 2017 Restricted Stock Unit grant agreement ("RSU agreement") previously disclosed and filed on Form 8-K. Mr. Uecker has not sold or in any other way disposed of shares in any manner other than pursuant to the contractual provisions of the RSU agreement. F2 · price: The market close price of $11.51 per share on June 3, 2019 was used to calculate the number of withheld shares. F3 · balance_after: Includes shares acquired by the Reporting Person pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 21:59 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Tax withholdingCommon Stock | 7,168 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-035292 · doc4.xml · nonDerivative · entry 1 UECKER DARRIN · CIK 0001276311 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,981 F1 · shares: The shares reflected on this Form 4 represent shares surrendered exclusively for the payment of tax obligations as set forth in Mr. Uecker's June 2017 RSU grant agreement previously disclosed and filed on Form 8-K. Mr. Uecker has not sold or in any other way disposed of shares in any manner other than pursuant to the contractual provisions of the RSU agreement. F2 · price: The market close price of $16.10 per share on June 1, 2018 was used to calculate the number of withheld shares. F3 · balance_after: Includes shares acquired by the Reporting Person pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 20:07 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 195,000 | $0.00 Strike: $30.99 | $0.00 |
DisclosureSEC source: 0001209191-17-038858 · doc4.xml · derivative · entry 3 UECKER DARRIN · CIK 0001276311 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 195,000 shares Expires 2027-06-07 F3 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a four year period that began on February 15, 2017, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 20:07 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 187,286 | $0.00 Strike: $30.99 | $0.00 |
DisclosureSEC source: 0001209191-17-038858 · doc4.xml · derivative · entry 2 UECKER DARRIN · CIK 0001276311 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,286 Underlying: Common Stock · 187,286 shares Expires 2027-06-07 F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a four year period that began on June 21, 2016, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 20:07 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantCommon Stock | 160,974 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-038858 · doc4.xml · nonDerivative · entry 1 UECKER DARRIN · CIK 0001276311 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,974 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU"). The RSUs will fully vest on June 1, 2018, subject to the Reporting Person's continued service as of that date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.